Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany

Publication | Open Access

DOI Full Paper Access

Citations

References

2020

Year

Andreas Schneeweiß, Johannes Ettl, Diana Lüftner, Matthias W. Beckmann, Erik Belleville, Peter A. Fasching, Tanja Fehm, Matthias Geberth, Lothar Häberle, Peyman Hadji,

The Breast